Distribution and metabolism of the retinoid, N-(4-methoxyphenyl)-all-trans-retinamide, the major metabolite of N-(4-hydroxyphenyl)-all-trans-retinamide, in female mice
- PMID: 1971569
Distribution and metabolism of the retinoid, N-(4-methoxyphenyl)-all-trans-retinamide, the major metabolite of N-(4-hydroxyphenyl)-all-trans-retinamide, in female mice
Abstract
The metabolism and disposition of N-(4-methoxyphenyl)-all-trans-retinamide (MPR), the major metabolite of N-(4-hydroxyphenyl)-all-trans-retinamide (4-HPR), were investigated in female B6D2F1 (BDF) mice. Following a single oral dose of 10 mg/kg, MPR distributed to the serum, liver, mammary gland, urinary bladder, and skin. The highest levels of MPR were detected in the liver and mammary gland, and the largest values for AUC were in the mammary gland followed by the skin and liver. The t1/2 for MPR was 5.1 hr in liver, 5.6 hr in serum, 18.7 hr in urinary bladder, 23.1 hr in skin, and 26.6 hr in mammary gland. MPR and five metabolites were detected; levels varied between tissues. One metabolite was 4-HPR; the other four, which eluted at 7, 12, 13, and 18 min, remain unidentified. The major metabolite of MPR was the 18-min metabolite and comprised 17% of total retinoid in skin and 14% in mammary gland. 4-HPR was only a minor metabolite of MPR; 4-HPR was not detectable in serum or urinary bladder and accounted for less than 4% of total retinoid in the other tissues. In mice dosed with 10 mg/kg 4-HPR, the parent compound, MPR, a putative 4-HPR ester, and three of the MPR metabolites (7, 13, and 18 min) were found. These data suggest that the interconversion of 4-HPR and MPR greatly favors formation of MPR.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
N-(4-hydroxyphenyl)-all-trans-retinamide pharmacokinetics in female rats and mice.Drug Metab Dispos. 1986 Nov-Dec;14(6):714-7. Drug Metab Dispos. 1986. PMID: 2877832
-
Effects of pretreatment with the retinoid N-(4-hydroxyphenyl)-all-trans-retinamide and phenobarbital on the disposition and metabolism of N-(4-hydroxyphenyl)-all-trans-retinamide in mice.Drug Metab Dispos. 1988 Nov-Dec;16(6):783-8. Drug Metab Dispos. 1988. PMID: 2907453
-
Liquid chromatography method for quantifying N-(4-hydroxyphenyl)retinamide and N-(4-methoxyphenyl)retinamide in tissues.J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Sep 5;808(2):125-30. doi: 10.1016/j.jchromb.2004.02.031. J Chromatogr B Analyt Technol Biomed Life Sci. 2004. PMID: 15261805
-
Retinoids and mammary gland differentiation.Ciba Found Symp. 1985;113:156-67. doi: 10.1002/9780470720943.ch10. Ciba Found Symp. 1985. PMID: 3896699 Review.
-
Chemoprevention of experimental carcinogenesis in animals.Prev Med. 1989 Sep;18(5):576-91. doi: 10.1016/0091-7435(89)90031-5. Prev Med. 1989. PMID: 2694156 Review.
Cited by
-
Analysis of fenretinide and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics.J Pharm Biomed Anal. 2017 Jan 5;132:117-124. doi: 10.1016/j.jpba.2016.09.046. Epub 2016 Sep 29. J Pharm Biomed Anal. 2017. PMID: 27701038 Free PMC article.
-
The hydroxyl functional group of N-(4-hydroxyphenyl)retinamide mediates cellular uptake and cytotoxicity in premalignant and malignant human epithelial cells.Free Radic Biol Med. 2010 Dec 15;49(12):2001-9. doi: 10.1016/j.freeradbiomed.2010.09.032. Epub 2010 Oct 23. Free Radic Biol Med. 2010. PMID: 20923701 Free PMC article.
-
Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases.Br J Pharmacol. 2011 Feb;162(4):989-99. doi: 10.1111/j.1476-5381.2010.01104.x. Br J Pharmacol. 2011. PMID: 21054342 Free PMC article.
-
Fenretinide activates caspases and induces apoptosis in gliomas.Clin Cancer Res. 1999 Aug;5(8):2230-5. Clin Cancer Res. 1999. PMID: 10473110 Free PMC article.